Global COPD Drugs Market Forecast to 2023 COPD Market Report | Page 22

List of Figures
Figure No.
Figure Title
Page No.
Figure 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD) 169
Figure 202: Middle East and North Africa, Population ages 65 and above (% of total) 169
Figure 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million) 170
Figure 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%) 171
Figure 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%) 171
Figure 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) 172
Figure 207: Exacerbation During the Study Over a Period of 12 Months (Part B) 198
Figure 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050) 211
Figure 209: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) 220
Figure 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million 223
Figure 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million 226
Figure 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million 229
Figure 213: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) 233
Figure 214: GSK, Revenues, 2013-2017 (USD Million) 236
Figure 215: GSK, Revenues, 2013-2017 (USD Million) 236
Figure 216: GSK, Revenue, By Segments, 2017(%) 236
Figure 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million) 236
Figure 218: GSK COPD Drugs Patent Expiry Details 237
Figure 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million) 237
Figure 220: AstraZeneca, Net Sales, 2013-2017 (USD Million) 239
(c) AZOTH Analytics
22